Advertisement


Howard Kaufman, MD, on Merkel Cell Carcinoma: Treatment Update

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

Advertisement

Howard Kaufman, MD, of Rutgers Cancer Institute of New Jersey, discusses a subgroup analysis of efficacy results on avelumab in chemotherapy-refractory metastatic Merkel cell carcinoma. (Abstract 80)



Related Videos

Issues in Oncology

Elizabeth Ann Mittendorf, MD, PhD, on ASCO-SITC Meeting Highlights: Expert Perspective

Elizabeth Ann Mittendorf, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses some of the top papers presented at the ASCO-SITC Symposium and how these present...

Solid Tumors

Prasad S. Adusumilli, MD, on Solid Tumors: CAR T Cells and Immune Checkpoint Blockade

Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses a way to promote functional persistence of CAR T cells as an ideal strategy for solid tumor immunotherap...

Issues in Oncology

Lawrence Fong, MD, on Novel T-Cell Checkpoint Combinations

Lawrence Fong, MD, of the University of California, San Francisco, discusses combination immunotherapy, now approved in melanoma, and the trials underway to explore other indications.

Lung Cancer

Roy S. Herbst, MD, PhD, on Lung Cancer With Immune Checkpoints: Promising Combinations

Roy S. Herbst, MD, PhD, of the Yale Cancer Center, discusses immunotherapy as a standard of care in lung cancer, critical biomarkers, and scientifically guided combination treatment, ...

CNS Cancers

Holger N. Lode, MD: Neuroblastoma Survival Update

Holger N. Lode, MD, of the University of Greifswald, discusses the survival of neuroblastoma patients treated with long-term infusion of the anti-GD2 antibody ch14.18/CHO and killer-c...

Advertisement

Advertisement



Advertisement